“340B Stakeholders Examine the Safety Net at Third Annual Summit”
More than 70 stakeholders, including grantees, patient advocates, clinical specialists, academic organizations, hospitals and the biopharmaceutical industry, convened in Washington in June, 2016 for the third National Leadership Summit on 340B. The third-annual summit, organized by the Alliance for Integrity and Reform of 340B (AIR 340B), focused on a critical aspect of the 340B program: the changing face of the safety net and how to best support those uninsured or vulnerable patients in need of the 340B program. Speakers included Congressional staff, policy thought leaders, representatives from community health centers, and a Member of Congress.
“As Congressional Interest in 340B Grows, 50+ House Offices Attend Briefing; Rep. Collins Raises Concerns Over 340B’s Failures to Serve Vulnerable Patients”
Panelists were joined by Congressman Chris Collins (R-NY), who in his introductory remarks spoke about his personal experience with the program as a former top hospital administrator. Rep. Collins called into question whether the program’s growth over the last two decades has truly led to more patients seeing the benefits.
“AIR 340B Hosts Hill Briefing on Program Sustainability & Implications for Patients”
Dozens of Hill offices came together to hear presentations from industry experts about the origins of the 340B program and the challenges that must be addressed to ensure the program’s sustainability.
“Broad Stakeholder Group Examines 340B Sustainability at Second National Summit”
At the second-annual summit, leaders from the federal government and a broad spectrum of stakeholder groups, including representatives of federal 340B grantees, patient and specialty organizations, industry and academic institutions and a disproportionate share hospital (DSH), continued an open dialogue about the benefits and shortfalls of the 340B Drug Pricing Program.
“Members Press for Specific Program Changes as Congress Holds First Hearing on 340B in Nearly a Decade”
For the first time in nearly a decade, the House Energy and Commerce Subcommittee on Health held a hearing to examine the 340B Drug Pricing Program. Members of Congress from both sides of the aisle raised questions about the program’s accountability and transparency and encouraged HRSA to address the administrative shortcomings of the program through regulatory action.